The Royal Treatment: Ligand Pharmaceuticals' Unlikely Rise to Prominence Investors are increasingly betting on royalty fueled pharmaceutical companies like Ligand Pharmaceuticals (LGND), with some viewing this as the latest iteration of Wall Street's fascination with high risk, high reward investments.
However, it's worth examining what drives this enthusiasm and whether it's sustainable.
Ligand's recent surge in interest can be attributed to its inclusion on two elite stock screens, which serve as a benchmark for savvy investors and money managers looking to make informed decisions about their portfolios.